Springboard Health Angels

At CGC Genomics (CGC) we are deeply committed to advancing the field of cancer care through complex, precision genomics analysis and report interpretation. We distill complex genomic data into concise, actionable insights for healthcare providers, reducing interpretation times and facilitating timely, personalized treatment recommendations for 10 million patients with metastatic cancer.​ Our years of experience interpreting and supporting thousands of the most complicated cancer genomics cases around the world enables CGC to offer healthcare providers timely, expert cancer genomics analysis and consultation support, delivering world-class expertise wherever and whenever needed.

Vivalyx is a healthcare company focused on improving organ transplantation outcomes. It specializes in developing a cost-effective solution for preserving organs, aiming to enhance their vitality and increase the available number for transplantation. The company's technology eliminates the need for donor blood or human products, making it a versatile option for various preservation applications. By doing so, Vivalyx supports doctors in extending organ viability, ultimately benefiting patients suffering from organ failure worldwide.

Yoneda Labs is a developer of AI-based software designed to assist chemists in optimizing reaction parameters essential for the synthesis of drugs and materials. The platform enables users to determine critical factors such as temperature, concentration, and catalyst, thereby enhancing the efficiency and speed of chemical laboratory processes. By leveraging advanced artificial intelligence, Yoneda Labs aims to streamline the development of chemical reactions, ultimately facilitating faster innovation in the pharmaceutical and material sciences industries.

deepeye Medical is a precision medicine platform focused on retinal diseases, specifically aimed at enhancing the treatment of prevalent conditions such as Age-related Macular Degeneration (AMD). The platform leverages artificial intelligence to provide ophthalmologists with valuable insights into therapy data and deep learning models, which aid in delivering personalized treatment plans for patients. By addressing the needs of healthcare providers, pharmaceutical companies, and payors, deepeye Medical seeks to improve therapeutic outcomes and reduce the incidence of blindness, a significant concern affecting 12% of the population in the EU and the US. The company's innovative approach aims to facilitate better decision-making in ophthalmic care, ultimately contributing to more effective management of retinal diseases.

PharmaCCX is a healthcare technology company established in 2017, headquartered in Boston with additional offices in Stockholm, San Mateo, and Zug. It operates a platform that facilitates pricing negotiations and procurement processes between oncology pharmaceutical companies and healthcare payers, aiming to accelerate patient access to necessary medicines. The platform offers a configurable infrastructure for planning, negotiating, and managing deals, enabling market access teams at pharma companies and payers to efficiently administer innovative payment models.

Tech-enabled healthcare solution for the underserved LGBTQIA+ community.

LEVY Health is a healthcare technology company that specializes in clinical decision support software for endocrine disorders. Its proprietary algorithm, based on established clinical guidelines, assists medical professionals in recommending accurate ICD-10 diagnoses and tailored therapeutic strategies. By leveraging this technology, LEVY Health significantly reduces the time to diagnosis from an average of 4.5 years to just a few weeks, thereby improving patient outcomes and healthcare efficiency.

Virtonomy GmbH is a Munich-based company that specializes in providing clinical trial services using virtual human, sheep, pig, and calf models. Founded in 2019, Virtonomy offers a platform that integrates digital twin models, AI, multi-physics simulations, and predictive analytics to enhance the development and evaluation of medical devices. The company delivers services such as anatomy studies, virtual fittings, pre-operative planning, and visualization through detailed image analysis and three-dimensional anatomical models. By enabling medical device manufacturers to optimize designs, reduce risks associated with anatomical variability, and develop patient-specific implants, Virtonomy facilitates a streamlined product development process. This approach not only shortens development timelines but also minimizes costs and risks linked to traditional clinical trials, allowing for safer and more efficient testing in a virtual environment.

Operator of a cell-based biotechnology platform designed to produce messenger ribonucleic acid(mRNA) therapeutics and vaccines. The company's platform uses cell engineering, computational biology, and precision fermentation to optimize the production of vaccinia capping enzymes, enabling medical professionals to provide optimal medicines to their patients.

Acorai is a medical device company focused on developing a non-invasive heart failure monitoring platform that centers around direct intracardiac pressure monitoring (ICPM). The company utilizes a unique combination of sensor technologies and machine learning to enable accurate and cost-effective heart failure management. Acorai's technology allows for the non-invasive monitoring of cardiac and pulmonary pressure through the analysis of acoustic, vibratory, and waveform data, making it the only proven method to enhance outcomes for heart failure patients. The device has received clinical validation and has been designated as an FDA Breakthrough Device, with plans to enter the market in 2025. By enabling healthcare professionals to proactively adjust medications, Acorai aims to reduce both the rates of heart failure re-hospitalization and mortality.

Syndi is a digital health support recommendation platform that utilizes machine learning and digital phenotyping, with a primary focus on mental health. The company develops technology-driven solutions aimed at enhancing individuals' health by providing effective and accessible support. Syndi's platform employs passive smartphone data collection to gather moment-to-moment information about users, allowing it to deliver personalized and immediate care. This innovative approach not only facilitates connections between patients and healthcare providers but also measures the effectiveness of applications and digital services in treating invisible disabilities. Through its commitment to leveraging technology and research, Syndi seeks to improve healthcare outcomes for its users.

Recovery Cat is a developer of a therapy collaboration platform designed for individuals with severe mental disorders. The company focuses on collective therapy planning and evaluation, enabling enhanced insights for both healthcare providers and patients. By monitoring patient responses to medical treatments for conditions such as schizophrenia, bipolar disorder, and recurrent depression, Recovery Cat empowers psychiatrists to adopt a patient-centric approach. This platform facilitates personalized follow-ups and provides insightful data, helping clinicians identify the most effective medications and detect patients at risk of relapses. Through its innovative solutions, Recovery Cat supports better engagement in treatment, ultimately aiming to improve outcomes for those affected by these mental health challenges.

Mirantus Health is a digital healthcare provider focused on enhancing access to care for underserved patients. It offers a combination of healthcare services through Mirantus Care and cloud-based solutions via Mirantus OS, which empower physicians to efficiently diagnose and treat patients who are traditionally hard to reach. By integrating point-of-care diagnostics with telemedicine, Mirantus enables specialist physicians to deliver care remotely, thus improving healthcare accessibility. The company aims to involve every specialist physician in Europe in its distributed healthcare model, ultimately striving to provide better access to care for over 100 million underserved patients while also helping physicians increase their earnings and reducing downstream costs for payors.

Akina is a Swiss company founded in 2021, headquartered in Zurich, that specializes in developing artificial intelligence healthcare software. The company focuses on enhancing physiotherapy by providing a platform that empowers patients to engage in independent therapy at home. Through its innovative software, Akina connects patients with healthcare providers for remote therapeutic monitoring and personalized guidance. The platform utilizes proprietary AI motion analysis and media streaming algorithms to facilitate automated case reviews and generate feedback for therapists. This approach aims to improve clinical outcomes and enhance the efficiency of care delivery, merging evidence-based therapy with engaging entertainment for a comprehensive treatment experience.

Phinomics is a precision-medicine platform that specializes in the discovery and development of novel therapeutics through the exploration of circular DNA targets. The company utilizes advanced genomic technologies, which include AI-driven platforms, single-cell analysis, and bioinformatics, to identify pathology-specific circular DNAs that have been previously overlooked. By focusing on extrachromosomal circular DNA, Phinomics aims to uncover new molecular markers that can enhance clinical diagnostics and drug discovery. This innovative approach addresses significant unmet needs in healthcare, enabling clinicians to improve prevention, diagnosis, and treatment of disorders linked to DNA alterations. Through its proprietary workflows and robust scientific foundations, Phinomics seeks to provide unprecedented resolution in precision care.

Rekoo is an online clinic for stroke healing. They provide optimal care for every stroke patient by returning them to the center. They offer care systems, but they don't find the support they need, resulting in deficient recovery outcomes and skyrocketing care costs.